<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02965898</url>
  </required_header>
  <id_info>
    <org_study_id>R16004</org_study_id>
    <nct_id>NCT02965898</nct_id>
  </id_info>
  <brief_title>The Effect of Vitamin D Substitution on the Development of Chronic Pancreatitis</brief_title>
  <official_title>The Effect of Vitamin D Substitution on Pancreatic Parenchyma and Development of Fibrosis After First Acute Alcoholic Pancreatitis: A Randomized Prospective Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tampere University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Orion Corporation, Orion Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Tampere University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute pancreatitis (AP) may develop to chronic pancreatitis (CP). In Finland, the ethiology
      is alcohol in about 80% of the cases. Several symptoms lower the quality of life in CP
      patients, including abdominal pain, exocrine and endocrine pancreatic insufficiency.

      Recently, the investigators and others have found that vitamin D may protect from the
      formation of fibrosis on cellular level. The investigators hypothesized that after the first
      AP they may be able to protect the formation of fibrosis leading to CP with Vitamin D, and
      designed this RCT.

      The aim is to study whether the investigators can prevent CP with vitamin D substitute.

      In this randomized controlled patient study, the patients after their first AP are randomized
      to have either a normal recommended (10 μ) or a largest safe dose (100 μg). of vitamin D
      substitute daily. The patients are examined by MRI/MRCP imaging and laboratory tests at the
      baseline after recovery from AP and yearly then after.

      Primary endpoint is the development of parenchymal changes possibly related to fibrosis.
      Secondary endpoints are the development of CP with Mannheim criteria, CP related
      complications and mortality.

      The first analysis will be done after 3 years.

      The enrollment will begin 26.9.2016
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The development of parenchymal changes possibly related to fibrosis after acute pancreatitis analysed by magnetic resonance cholangiopancreatography imaging texture analysis</measure>
    <time_frame>3 years</time_frame>
    <description>A radiologist analyses the pancreatic parenchymal changes from MRCP images</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The development of chronic pancreatitis (CP) with Mannheim criteria</measure>
    <time_frame>3 years</time_frame>
    <description>The diagnostic Mannheim criteria include laboratory tests for measuring the endocrine and exocrine function of the pancreas and MRI/MRCP for measuring pancreatic duct lesions and calcifications.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The development of complications related to chronic pancreatitis</measure>
    <time_frame>3 years</time_frame>
    <description>The complications are registered from the participants medical records.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality related to chronic pancreatitis</measure>
    <time_frame>3 years</time_frame>
    <description>The mortality is registered from the participants medical records.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">260</enrollment>
  <condition>Chronic Pancreatitis</condition>
  <arm_group>
    <arm_group_label>Vitamin D 100ug</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The highest safest dose. Expected to lower risk of chronic pancreatitis after acute pancreatitis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin D 10ug</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo dose. Minimal recommended dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D 100ug</intervention_name>
    <description>Vitamin D 100 ug from Orion Pharma. Safest highest daily dose of vitamin D.</description>
    <arm_group_label>Vitamin D 100ug</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D 10ug</intervention_name>
    <description>Placebo dose. Minimal recommended dose.</description>
    <arm_group_label>Vitamin D 10ug</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  First alcohol induced acute pancreatitis

          -  Willing to participate in a 3 year RCT

        Exclusion Criteria:

          -  Renal failure

          -  Hypercalcemia

          -  High serum levels of vitamin D

          -  Unwilling to participate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>101 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Johanna Laukkarinen, Ass professor</last_name>
    <email>johanna.laukkarinen@pshp.fi</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mikael Parhiala</last_name>
    <email>mikael.parhiala@fimnet.fi</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tampere University Hospital</name>
      <address>
        <city>Tampere</city>
        <zip>33520</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johanna Laukkarinen, Ass professor</last_name>
      <email>johanna.laukkarinen@pshp.fi</email>
    </contact>
    <contact_backup>
      <last_name>Mikael Parhiala</last_name>
      <phone>+358443097406</phone>
      <email>mikael.parhiala@fimnet.fi</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <link>
    <url>http://www.efsa.europa.eu/en/efsajournal/pub/2813</url>
    <description>Scientific Opinion on the Tolerable Upper Intake Level of vitamin D</description>
  </link>
  <reference>
    <citation>Sherman MH, Yu RT, Engle DD, Ding N, Atkins AR, Tiriac H, Collisson EA, Connor F, Van Dyke T, Kozlov S, Martin P, Tseng TW, Dawson DW, Donahue TR, Masamune A, Shimosegawa T, Apte MV, Wilson JS, Ng B, Lau SL, Gunton JE, Wahl GM, Hunter T, Drebin JA, O'Dwyer PJ, Liddle C, Tuveson DA, Downes M, Evans RM. Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy. Cell. 2014 Sep 25;159(1):80-93. doi: 10.1016/j.cell.2014.08.007.</citation>
    <PMID>25259922</PMID>
  </reference>
  <reference>
    <citation>Bläuer M, Sand J, Laukkarinen J. Physiological and clinically attainable concentrations of 1,25-dihydroxyvitamin D3 suppress proliferation and extracellular matrix protein expression in mouse pancreatic stellate cells. Pancreatology. 2015 Jul-Aug;15(4):366-71. doi: 10.1016/j.pan.2015.05.044. Epub 2015 May 14.</citation>
    <PMID>26005021</PMID>
  </reference>
  <reference>
    <citation>Hathcock JN, Shao A, Vieth R, Heaney R. Risk assessment for vitamin D. Am J Clin Nutr. 2007 Jan;85(1):6-18. Review.</citation>
    <PMID>17209171</PMID>
  </reference>
  <reference>
    <citation>Steffensen LH, Jørgensen L, Straume B, Mellgren SI, Kampman MT. Can vitamin D supplementation prevent bone loss in persons with MS? A placebo-controlled trial. J Neurol. 2011 Sep;258(9):1624-31. doi: 10.1007/s00415-011-5980-6. Epub 2011 Mar 13.</citation>
    <PMID>21400196</PMID>
  </reference>
  <reference>
    <citation>Stallings VA, Schall JI, Hediger ML, Zemel BS, Tuluc F, Dougherty KA, Samuel JL, Rutstein RM. High-dose vitamin D3 supplementation in children and young adults with HIV: a randomized, placebo-controlled trial. Pediatr Infect Dis J. 2015 Feb;34(2):e32-40. doi: 10.1097/INF.0000000000000483.</citation>
    <PMID>24988118</PMID>
  </reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 23, 2016</study_first_submitted>
  <study_first_submitted_qc>November 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2016</study_first_posted>
  <last_update_submitted>December 17, 2017</last_update_submitted>
  <last_update_submitted_qc>December 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tampere University Hospital</investigator_affiliation>
    <investigator_full_name>Mikael Parhiala</investigator_full_name>
    <investigator_title>PhD canditate</investigator_title>
  </responsible_party>
  <keyword>chronic pancreatitis</keyword>
  <keyword>vitamin d</keyword>
  <keyword>pancreatitis</keyword>
  <keyword>Pancreatic stellate cell</keyword>
  <keyword>rct</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatitis</mesh_term>
    <mesh_term>Pancreatitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The data will be written into an article, which shall be displayed in a national and international forum.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

